GTC 2020: De Novo Protein Design of Epitope-Directed Inhibitors
After clicking “Watch Now” you will be prompted to login or join.
Click “Watch Now” to login or join the NVIDIA Developer Program.
De Novo Protein Design of Epitope-Directed Inhibitors
Mohammad ElGamacy, Friedrich Miescher Laboratory of the Max Planck Society
Protein drugs have revolutionized modern cancer therapeutics, as protein-based binders can effectively target molecules that are otherwise undruggable by small molecules. Presently, such binders are based on monoclonal antibodies, which are developed and engineered through lengthy and resource-intensive processes of iterative optimization that are empirically guided. Conversely, de novo protein design can offer a rational means for generating new binders with bespoke scaffolds, guided by physics-based computations. Here, we'll present our work on developing a purpose-built, GPU-accelerated computational pipeline for designing protein-based binders de novo. As a proof of principle, we designed proteins that target a key modulator of cancer metastasis. Our experimental characterization of only a few design candidates resulted in binders with strong binding affinities. Solving the structure of one design showed atomic-level agreement between the design model and the determined structure.